107th Congress

Session II - P.L. 107-109  Best Pharmaceuticals for Children Act

On January 4, 2002, the President signed into law S. 1789, the Best Pharmaceuticals for Children Act, as P.L. 107-109. This legislation reauthorizes the pediatric studies provision of the Food and Drug Administration Modernization and Accountability Act of 1997. S. 1789 encourages pharmaceutical companies to conduct pediatric studies of new and already marketed drugs that are currently used in pediatric populations but are not labeled for such use by extending their market exclusivity. The law authorizes $200 million in FY 2002 and such sums as are necessary for each of the five succeeding fiscal years, for pediatric studies of drugs. For further information, go to the Thomas Web Site.

Legislative Updates: Best Pharmaceuticals for Children Act .

For a chronology of legislation affecting NIH, refer to the NIH Almanac.